Pα+ Psychedelic Bulletin #209: Aussie Insurer Covers Psilocybin for TRD; atai Scores $11.4M NIDA Grant; First Look at Real-World Outcomes from Oregon Psilocybin Clients; Pipeline Updates

We forgo our introductory remarks today, as it’s been a busy couple of weeks since we published our last Bulletin, so there is plenty to dive into in this Issue… *** Last week, atai Life Sciences announced that it has been awarded a UG3/UGH grant[1] from the U.S. National Institute on Drug Abuse (NIDA), which is part of the National Institutes of Health (NIH), to optimise and develop a…

Source